RetaMaps

Vitality Telehealth, LLC

Vitality Telehealth (telehealth; WY registered address in dump) · 1309 Coffeen Avenue · Sheridan, WY 82801

Listing updated October 2, 2026

Retatrutide outlook for this practice

No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.

About this practice

Vitality Telehealth is a comprehensive telehealth practice offering supportive/medical weight loss, testosterone replacement, bioidentical hormone therapy, and peptide/regenerative care, with clinician Lori Smith, DNP, APRN, FNP-C. The official site markets virtual visits from home, highlights Arkadelphia, AR, and states it serves Arkansas, Florida, South Dakota, and Wyoming. Its FAQ names compounded semaglutide and tirzepatide as weight-loss injection options. The Sheridan, WY street address in listings is a registered-agent style location, not an in-person GLP-1 clinic.

Services & access

Advertises semaglutide todayYes
Advertises tirzepatide todayYes
Telehealth visitsYes
Cash pay acceptedYes
Accepts insurance — per practice website—
Accepting new patients — per practice websiteYes

"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.

Clinicians

  • Lori Smith, DNP, APRN, FNP-C

Nearby providers in Sheridan

Retatrutide status
Phase 3 complete · Not FDA-approvedUpdated October 2, 2026

Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.

Development
Phase 3 complete
FDA status
Submission planned — Q1 2027 (Lilly guidance)
Availability
Not commercially available
Access routes
Clinical trials, or Lilly's expanded access program (physician must apply)

Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)

Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs